MSTN and hydrops fetalis: For instance, previous clinical studies have shown some benefit in cardiac myocyte protection due to an SGLT2 inhibitor-related increase in serum levels of various adipomyokines, such as apelin and irisin, and a decrease in myostatin in HF [58,59,60].